<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Francica JR</submitter><funding>CCR NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>6565</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4403371</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6</volume><pubmed_abstract>Developing predictive animal models to assess how candidate vaccines and infection influence the ontogenies of Envelope (Env)-specific antibodies is critical for the development of an HIV vaccine. Here we use two nonhuman primate models to compare the roles of antigen persistence, diversity and innate immunity. We perform longitudinal analyses of HIV Env-specific B-cell receptor responses to SHIV(AD8) infection and Env protein vaccination with eight different adjuvants. A subset of the SHIV(AD8)-infected animals with higher viral loads and greater Env diversity show increased neutralization associated with increasing somatic hypermutation (SHM) levels over time. The use of adjuvants results in increased ELISA titres but does not affect the mean SHM levels or CDR H3 lengths. Our study shows</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.</pubmed_title><pmcid>PMC4403371</pmcid><funding_grant_id>HHSN261200800001E</funding_grant_id><funding_grant_id>HHSN261200800001C</funding_grant_id><pubmed_authors>Young A</pubmed_authors><pubmed_authors>Shingai M</pubmed_authors><pubmed_authors>Schmidt B</pubmed_authors><pubmed_authors>Bouffard G</pubmed_authors><pubmed_authors>Masiello C</pubmed_authors><pubmed_authors>Dekhtyar M</pubmed_authors><pubmed_authors>Nishimura Y</pubmed_authors><pubmed_authors>Lynch RM</pubmed_authors><pubmed_authors>De Gregorio E</pubmed_authors><pubmed_authors>Singh M</pubmed_authors><pubmed_authors>Gupta J</pubmed_authors><pubmed_authors>O'Hagan DT</pubmed_authors><pubmed_authors>McDowell J</pubmed_authors><pubmed_authors>Sheng Z</pubmed_authors><pubmed_authors>Sison C</pubmed_authors><pubmed_authors>Kepler TB</pubmed_authors><pubmed_authors>Brooks S</pubmed_authors><pubmed_authors>Park M</pubmed_authors><pubmed_authors>Yamamoto T</pubmed_authors><pubmed_authors>Francica JR</pubmed_authors><pubmed_authors>Malyala P</pubmed_authors><pubmed_authors>Darko S</pubmed_authors><pubmed_authors>Shapiro L</pubmed_authors><pubmed_authors>Coleman H</pubmed_authors><pubmed_authors>Seder RA</pubmed_authors><pubmed_authors>Maduro Q</pubmed_authors><pubmed_authors>NISC Comparative Sequencing Program</pubmed_authors><pubmed_authors>Barnabas B</pubmed_authors><pubmed_authors>Vemulapalli M</pubmed_authors><pubmed_authors>Douek DC</pubmed_authors><pubmed_authors>Montemayor C</pubmed_authors><pubmed_authors>Wolinsky D</pubmed_authors><pubmed_authors>Mullikin J</pubmed_authors><pubmed_authors>Keele BF</pubmed_authors><pubmed_authors>Riebow N</pubmed_authors><pubmed_authors>Thomas J</pubmed_authors><pubmed_authors>Koup RA</pubmed_authors><pubmed_authors>Legaspi R</pubmed_authors><pubmed_authors>Thomas P</pubmed_authors><pubmed_authors>Barnett SW</pubmed_authors><pubmed_authors>Schandler K</pubmed_authors><pubmed_authors>Flynn BJ</pubmed_authors><pubmed_authors>Ho SL</pubmed_authors><pubmed_authors>Valiante NM</pubmed_authors><pubmed_authors>Maskeri B</pubmed_authors><pubmed_authors>Blakesley R</pubmed_authors><pubmed_authors>Martin MA</pubmed_authors><pubmed_authors>Schmidt SD</pubmed_authors><pubmed_authors>Matus-Nicodemos R</pubmed_authors><pubmed_authors>Stantripop M</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Mascola JR</pubmed_authors><pubmed_authors>Guan X</pubmed_authors><pubmed_authors>Nason M</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>Gregory M</pubmed_authors><pubmed_authors>Ramesh A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.</name><description>Developing predictive animal models to assess how candidate vaccines and infection influence the ontogenies of Envelope (Env)-specific antibodies is critical for the development of an HIV vaccine. Here we use two nonhuman primate models to compare the roles of antigen persistence, diversity and innate immunity. We perform longitudinal analyses of HIV Env-specific B-cell receptor responses to SHIV(AD8) infection and Env protein vaccination with eight different adjuvants. A subset of the SHIV(AD8)-infected animals with higher viral loads and greater Env diversity show increased neutralization associated with increasing somatic hypermutation (SHM) levels over time. The use of adjuvants results in increased ELISA titres but does not affect the mean SHM levels or CDR H3 lengths. Our study shows</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Apr</publication><modification>2026-04-13T21:09:33.944Z</modification><creation>2019-03-27T01:50:12Z</creation></dates><accession>S-EPMC4403371</accession><cross_references><pubmed>25858157</pubmed><doi>10.1038/ncomms7565</doi></cross_references></HashMap>